Brown Advisory Inc. Has $85.05 Million Holdings in Eli Lilly and Company $LLY

Brown Advisory Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 109,103 shares of the company’s stock after purchasing an additional 1,122 shares during the quarter. Brown Advisory Inc.’s holdings in Eli Lilly and Company were worth $85,049,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. SCS Capital Management LLC boosted its position in Eli Lilly and Company by 184.3% during the second quarter. SCS Capital Management LLC now owns 18,334 shares of the company’s stock valued at $14,292,000 after purchasing an additional 11,886 shares during the last quarter. GeoWealth Management LLC increased its position in shares of Eli Lilly and Company by 2.1% during the 2nd quarter. GeoWealth Management LLC now owns 4,320 shares of the company’s stock worth $3,368,000 after purchasing an additional 90 shares during the last quarter. Epoch Investment Partners Inc. raised its stake in shares of Eli Lilly and Company by 2.5% during the 2nd quarter. Epoch Investment Partners Inc. now owns 175,353 shares of the company’s stock worth $136,693,000 after purchasing an additional 4,299 shares in the last quarter. Royal Fund Management LLC boosted its holdings in shares of Eli Lilly and Company by 6.6% in the 2nd quarter. Royal Fund Management LLC now owns 4,205 shares of the company’s stock valued at $3,278,000 after buying an additional 262 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in shares of Eli Lilly and Company by 2.2% in the 2nd quarter. Baird Financial Group Inc. now owns 266,569 shares of the company’s stock valued at $207,799,000 after buying an additional 5,851 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on LLY. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a report on Monday, November 10th. National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a research note on Monday. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. BMO Capital Markets set a $1,200.00 price objective on Eli Lilly and Company in a research report on Thursday. Finally, Guggenheim reaffirmed a “buy” rating and set a $1,163.00 target price on shares of Eli Lilly and Company in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,087.32.

Eli Lilly and Company Trading Down 0.5%

Shares of LLY stock opened at $1,009.26 on Friday. The firm has a market cap of $954.13 billion, a P/E ratio of 49.38, a PEG ratio of 1.13 and a beta of 0.37. The company has a 50 day moving average of $918.84 and a 200-day moving average of $809.30. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the firm posted $1.18 earnings per share. The company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.